Review



cd34 cell fractions  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Miltenyi Biotec cd34 cell fractions
    Differentiation of <t>CB-CD34+</t> cells in a feeder- and serum-free culture system. A, Schematic of culture system. B, Conceptual schema of human T-cell development. CD7, CD5, and CD1a are sequentially expressed on <t>CD34+</t> cells entering into the thymus (DN cells), and develop into CD4- or CD8-expressing single positive (SP) cells through immature SP (iSP) and immature double-positive (iDP). Finally, mature SP T cells leave thymus and spread to periphery. C, Representative histograms and flow cytometry plots on day 14. Mean ± SEM values are presented for percent of CD7+ and CD7+CD5+ cells. D, The CD7+ (proT1) cell numbers on day 14 were different between groups without AA under ambient air and groups with AA under physioxia. CD7+ cell number showed differences between physioxia and ambient air groups (n = 9, two-way ANOVA, *P < .05, **P < .01). E, CD7+CD5+ (proT2) cell numbers showed differences between ambient air and physioxia groups (n = 9, two-way ANOVA, *P < .05). F, Folds of numbers of CD33+ (myeloid) cells on day 14 (n = 4, *P < .05). Cell numbers were normalized as cell numbers plated into one well (4000 CD34 + HSC/HPCs). Plots are presented as mean ± SEM. H, physioxia; HA, physioxia with AA; N, ambient air (non-physioxia); NA, ambient air with AA; NS, not significant
    Cd34 Cell Fractions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34+MicroBead+Kit%2C+human+-+lyophilized/pmc07901063-38-0-12
    Average 97 stars, based on 152 article reviews
    cd34 cell fractions - by Bioz Stars, 2026-09
    97/100 stars

    Images

    1) Product Images from "Physioxia enhances T-cell development ex vivo from human hematopoietic stem and progenitor cells"

    Article Title: Physioxia enhances T-cell development ex vivo from human hematopoietic stem and progenitor cells

    Journal: Stem cells (Dayton, Ohio)

    doi: 10.1002/stem.3259

    Differentiation of CB-CD34+ cells in a feeder- and serum-free culture system. A, Schematic of culture system. B, Conceptual schema of human T-cell development. CD7, CD5, and CD1a are sequentially expressed on CD34+ cells entering into the thymus (DN cells), and develop into CD4- or CD8-expressing single positive (SP) cells through immature SP (iSP) and immature double-positive (iDP). Finally, mature SP T cells leave thymus and spread to periphery. C, Representative histograms and flow cytometry plots on day 14. Mean ± SEM values are presented for percent of CD7+ and CD7+CD5+ cells. D, The CD7+ (proT1) cell numbers on day 14 were different between groups without AA under ambient air and groups with AA under physioxia. CD7+ cell number showed differences between physioxia and ambient air groups (n = 9, two-way ANOVA, *P < .05, **P < .01). E, CD7+CD5+ (proT2) cell numbers showed differences between ambient air and physioxia groups (n = 9, two-way ANOVA, *P < .05). F, Folds of numbers of CD33+ (myeloid) cells on day 14 (n = 4, *P < .05). Cell numbers were normalized as cell numbers plated into one well (4000 CD34 + HSC/HPCs). Plots are presented as mean ± SEM. H, physioxia; HA, physioxia with AA; N, ambient air (non-physioxia); NA, ambient air with AA; NS, not significant
    Figure Legend Snippet: Differentiation of CB-CD34+ cells in a feeder- and serum-free culture system. A, Schematic of culture system. B, Conceptual schema of human T-cell development. CD7, CD5, and CD1a are sequentially expressed on CD34+ cells entering into the thymus (DN cells), and develop into CD4- or CD8-expressing single positive (SP) cells through immature SP (iSP) and immature double-positive (iDP). Finally, mature SP T cells leave thymus and spread to periphery. C, Representative histograms and flow cytometry plots on day 14. Mean ± SEM values are presented for percent of CD7+ and CD7+CD5+ cells. D, The CD7+ (proT1) cell numbers on day 14 were different between groups without AA under ambient air and groups with AA under physioxia. CD7+ cell number showed differences between physioxia and ambient air groups (n = 9, two-way ANOVA, *P < .05, **P < .01). E, CD7+CD5+ (proT2) cell numbers showed differences between ambient air and physioxia groups (n = 9, two-way ANOVA, *P < .05). F, Folds of numbers of CD33+ (myeloid) cells on day 14 (n = 4, *P < .05). Cell numbers were normalized as cell numbers plated into one well (4000 CD34 + HSC/HPCs). Plots are presented as mean ± SEM. H, physioxia; HA, physioxia with AA; N, ambient air (non-physioxia); NA, ambient air with AA; NS, not significant

    Techniques Used: Expressing, Flow Cytometry

    HSC/HPC populations in physioxia vs ambient air groups. Cell numbers of (A) HSC/HPC (CD34+CD38−), (B) HSC (CD34+CD38−CD45RA−CD90+), and (C) multipotent progenitor (MPP, CD34+CD38−CD45RA−CD90−) were not different between physioxia and ambient air groups. D, Higher numbers of Lymphoid-primed multipotent progenitors (LMPP, CD34+CD38−CD45RA+CD90lo/−CD10−) and multi-lymphoid progenitors (MLP, CD34+CD38−CD45RA+CD90lo/−D10+) were observed in physioxia groups than in ambient air groups (P = .056) on day 7 (n = 3). E, Gene expression of the Notch1 signaling pathway (Notch1, HES1, DELTEX, TCF7, and GATA3) and PU.1 were not differently expressed between physioxia and ambient air groups at 48 hours (n = 4). Data are expressed as mean ± SEM. H, physioxia; HA, physioxia with AA; N, ambient air; NA, ambient air with AA; NS, not significant
    Figure Legend Snippet: HSC/HPC populations in physioxia vs ambient air groups. Cell numbers of (A) HSC/HPC (CD34+CD38−), (B) HSC (CD34+CD38−CD45RA−CD90+), and (C) multipotent progenitor (MPP, CD34+CD38−CD45RA−CD90−) were not different between physioxia and ambient air groups. D, Higher numbers of Lymphoid-primed multipotent progenitors (LMPP, CD34+CD38−CD45RA+CD90lo/−CD10−) and multi-lymphoid progenitors (MLP, CD34+CD38−CD45RA+CD90lo/−D10+) were observed in physioxia groups than in ambient air groups (P = .056) on day 7 (n = 3). E, Gene expression of the Notch1 signaling pathway (Notch1, HES1, DELTEX, TCF7, and GATA3) and PU.1 were not differently expressed between physioxia and ambient air groups at 48 hours (n = 4). Data are expressed as mean ± SEM. H, physioxia; HA, physioxia with AA; N, ambient air; NA, ambient air with AA; NS, not significant

    Techniques Used: Gene Expression

    Maturation of progenitor T cells on artificial thymic organoid cultures (ATO). A, Experimental schema. B, ATO at week 6. Images of ATOs divided by four or nine pieces at ×10 magnification were taken using inverted microscope (Eclipse Ts2R, Nikon, Tokyo, Japan), then merged those into one images using a large imaging stitching tool with NIS-elements Basic Research software (Nikon). C, Representative flow cytometry plot showing progenitor T cells and T-cell development on ATOs. Week 2 is the timing of placing progenitor cells onto ATOs, and week 6 is the timing for harvesting ATO cells for further analysis. More abundant expression of progenitor T and mature T-cell markers on cells were noted at week 6 than at week 2, with a comparison of cells maintained under ambient air (21% O2) vs under physioxia (5% O2) (n = 3)
    Figure Legend Snippet: Maturation of progenitor T cells on artificial thymic organoid cultures (ATO). A, Experimental schema. B, ATO at week 6. Images of ATOs divided by four or nine pieces at ×10 magnification were taken using inverted microscope (Eclipse Ts2R, Nikon, Tokyo, Japan), then merged those into one images using a large imaging stitching tool with NIS-elements Basic Research software (Nikon). C, Representative flow cytometry plot showing progenitor T cells and T-cell development on ATOs. Week 2 is the timing of placing progenitor cells onto ATOs, and week 6 is the timing for harvesting ATO cells for further analysis. More abundant expression of progenitor T and mature T-cell markers on cells were noted at week 6 than at week 2, with a comparison of cells maintained under ambient air (21% O2) vs under physioxia (5% O2) (n = 3)

    Techniques Used: Inverted Microscopy, Imaging, Software, Flow Cytometry, Expressing, Comparison

    Effect of physioxia vs ambient air during the maturation phase in ATOs. A, Experimental schema. B, ATO cell numbers under physioxia (5% O2) were increased more than those under ambient air (21% O2). Cell numbers were normalized by cell numbers placed onto one ATO (7500 progenitors/ATO) and cell numbers plated into one well (4000 CD34+ cells/well) (n = 3, two-way ANOVA, *P < .05). C, Cell numbers of CD7+CD1a+ precursor T cells per 4000 CD34+ cells between physioxia vs ambient air groups in ATOs (n = 3, two-way ANOVA, **P < .01). D-F, Numbers of T-cell subsets per 4000 CD34+ cells between physioxia vs ambient air groups in ATOs on week 6 (n = 3, two-way ANOVA, *P < .05). Data are presented as mean ± SEM. Diff., Differentiation; Mat., Maturation; NS, not significant
    Figure Legend Snippet: Effect of physioxia vs ambient air during the maturation phase in ATOs. A, Experimental schema. B, ATO cell numbers under physioxia (5% O2) were increased more than those under ambient air (21% O2). Cell numbers were normalized by cell numbers placed onto one ATO (7500 progenitors/ATO) and cell numbers plated into one well (4000 CD34+ cells/well) (n = 3, two-way ANOVA, *P < .05). C, Cell numbers of CD7+CD1a+ precursor T cells per 4000 CD34+ cells between physioxia vs ambient air groups in ATOs (n = 3, two-way ANOVA, **P < .01). D-F, Numbers of T-cell subsets per 4000 CD34+ cells between physioxia vs ambient air groups in ATOs on week 6 (n = 3, two-way ANOVA, *P < .05). Data are presented as mean ± SEM. Diff., Differentiation; Mat., Maturation; NS, not significant

    Techniques Used:



    Similar Products

    96
    Miltenyi Biotec cd34 fraction
    Cd34 Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34+MicroBead+Kit+UltraPure%2C+human/bio_rxiv__64898__2025__12__22__695871-246-1-6
    Average 96 stars, based on 1 article reviews
    cd34 fraction - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd34 cell fractions
    Cd34 Cell Fractions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34-VioBlue/us12203096-489-17-31
    Average 99 stars, based on 1 article reviews
    cd34 cell fractions - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd34 cell fraction
    Cd34 Cell Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34-VioBlue/pm39277669-53-1-17
    Average 99 stars, based on 1 article reviews
    cd34 cell fraction - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Qiagen cd34 cell fraction
    Cd34 Cell Fraction, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/miRNeasy+Micro+Kit/pmc11604037-358-7-18
    Average 99 stars, based on 1 article reviews
    cd34 cell fraction - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    90
    Glaxo Smith autologous cd34+-enriched cell fraction strimvelis
    FDA/EMA approved gene therapy product for rare monogenic diseases
    Autologous Cd34+ Enriched Cell Fraction Strimvelis, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/strimvelis/pmc11222908-222-7-8
    Average 90 stars, based on 1 article reviews
    autologous cd34+-enriched cell fraction strimvelis - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    FDA/EMA approved gene therapy product for rare monogenic diseases

    Journal: Clinical and Experimental Pediatrics

    Article Title: Development of orphan drugs for rare diseases

    doi: 10.3345/cep.2023.00535

    Figure Lengend Snippet: FDA/EMA approved gene therapy product for rare monogenic diseases

    Article Snippet: For instance, an autologous CD34+-enriched cell fraction, Strimvelis (GlaxoSmithKline plk, London, UK), which contains CD34+ cells transduced with a retroviral vector that encodes the human ADA cDNA sequence for ADA deficiency (introduced in 2016), and voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics, Philadelphia, USA), for retinal dystrophy caused by mutations in the RPE65 gene, were approved by the FDA in 2017 at a cost of $850,000 per eye [ ].

    Techniques: Plasmid Preparation, In Vivo, Ex Vivo, Mutagenesis, Modification, Variant Assay